First-line treatment of mCapOX plus cetuximab versus mFOLFOX6 plus cetuximab for metastatic left-sided CRC patients with wild-type RAS/BRAF genes: a multicenter, randomised, phase 2 study
收藏NIAID Data Ecosystem2026-03-12 收录
官方服务：
资源简介：
Interventions: Experimental groupA:mCapOX+ Cetuximab;Experimental groupB:mFOLFOX6+ Cetuximab Primary outcome(s): Progression free survival;Progression free survival Study Design: Parallel
创建时间：
2021-07-15
